An individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.
B. Khalil
No relevant relationships to disclose
J. M. Hudson
No relevant relationships to disclose
R. Williams
No relevant relationships to disclose
B. Lloyd
No relevant relationships to disclose
L. M. Milot
No relevant relationships to disclose
M. Atri
No relevant relationships to disclose
A. Kiss
No relevant relationships to disclose
P. Burns
Honoraria - Pfizer
G. A. Bjarnason
Honoraria - Pfizer
Research Funding - Pfizer